Sign in
WithdrawnPhase 1

Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

Key facts

Who runs it
The University of Texas Health Science Center at San Antonio
Where
San Antonio, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 1
Started
Jun 2023
Expected to end
Dec 2026
Type of study
Interventional, 4 groups
Treatments tested
  • bexmarilimab (FP-1305)
  • Pembrolizumab
Record updated
20 July 2023
Why it stopped
No participants were enrolled, the study was inactivated with the IRB on May 15, 2023. The sponsor notified the PI that a Phase II trial had been allowed to proceed by the FDA.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (21)Hide the full registry criteria

Who can take part

  • Able to provide written Informed Consent
  • Aged ≥ 18 years
  • Tumor sample obtained less than six months from the date of consent
  • Histologically confirmed NSCLC eligible for pembrolizumab as standard of care
  • Known tumor PD-L1 TPS score
  • Measurable disease based on RECIST 1.1 as determined by the site
  • Women of child-bearing potential must have a negative pregnancy test prior to trial entry and cycle 1 day 1 and should not be breast feeding
  • Women of child-bearing potential and men who have partners of child-bearing potential must be willing to practice highly effective contraception for the duration of the trial and for three months after the completion of treatment

Who cannot take part

  • Less than 21 days since the last dose of intravenous anticancer chemotherapy or less than five half-lives from a small molecule targeted therapy or oral anticancer chemotherapy before the first bexmarilimab administration
  • Any immunotherapy within preceding 3 weeks from the first bexmarilimab administration
  • Has untreated central nervous system (CNS) metastases and/or carcinomatous meningitis identified either on the baseline brain imaging obtained during the screening period. Subjects whose brain metastases have been treated may participate provided they show radiographic stability (defined as 2 brain images, both of which are obtained after treatment to the brain metastases. These imaging scans should both be obtained at least four weeks apart and show no evidence of intracranial progression). In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have returned to baseline or resolved. Any steroids administered as part of this therapy must be completed at least three days prior to study medication
  • Investigational therapy or major surgery within 4 weeks from the date of consent
  • Subject has not recovered from the previous therapies to Grade 1 severity as classified by the NCI-CTCAE version 5.0 (except Grade 2 alopecia, neuropathy or thyroid disorders)
  • The subject requires systemic corticosteroid or other immunosuppressive treatment
  • Use of live (attenuated) vaccines for 30 days prior to the start of study treatment, d during treatment, and until last visit
  • Prior therapy for advanced stage or metastatic disease
  • Active clinically serious infection >grade 2 NCI-CTCAE version 5.0 (Appendix 6) within preceding 2 weeks from the date of consent
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Any condition that study investigators consider an impediment to safe trial participation
  • Pregnant or lactating women
  • Subject is unwilling or unable to comply with treatment and trial instructions

Where in United States

  • Mays Cancer Center, UT Health San AntonioSan Antonio, United States

About the trial

What the trial wants to find out

This study enrolls patients with Non-small cell lung cancer and treats them with the investigational drug Bexmarilimab (FP-1305) plus standard of care Pembrolizumab to block Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1). Treating with an antiCLEVER-1 antibody, such as bexmarilimab, could lead to immune system activation, which, in turn, may lead to cancer elimination.

The 4 groups in the trial

  • Cohort 1Treatment being tested

    Study patients will receive 0.1-1 mg/kg bexmarilimab (FP-1350) given in combination with Pembrolizumab 200mg IV once every three weeks. The first subject will be started on 0.1mg to establish toleration, for one dose, and then the dose will be escalated to 1mg. This subject will be included in Cohort 1 data.

    Treatment: bexmarilimab (FP-1305) and Pembrolizumab

  • Cohort 2Treatment being tested

    Study participants will receive 3mg/kg Bexmarilimab given in combination with Pembrolizumab 200mg IV once every three weeks. 3 participants will need to complete this level before the next cohort dosing begins.

    Treatment: bexmarilimab (FP-1305) and Pembrolizumab

  • Cohort 3Treatment being tested

    Study participants will receive 10 mg/kg Bexmarilimab plus pembrolizumab 200mg IV once every 3 weeks. 3 participants will need to complete this level before the next cohort dosing begins.

    Treatment: bexmarilimab (FP-1305) and Pembrolizumab

  • Cohort 4Treatment being tested

    Study participants will receive 30 mg/kg Bexmarilimab plus pembrolizumab 200mg IV once every 3 weeks.

    Treatment: bexmarilimab (FP-1305) and Pembrolizumab

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Tolerability of Bexmarilimab Plus Pembrolizumab for Patients With Advanced (Inoperable or Metastatic) Non-small Cell Lung Cancer (NSCLC)
Record updated
20 July 2023